Hisun Pharma: Signed a licensing agreement with AbbVie for Nav1.8 inhibitors.

The company has signed an exclusive license agreement with AbbVie in which AbbVie is granted exclusive rights to develop, produce, and commercialize the Nav1.8 project globally, excluding Mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region. As part of the consideration for the license transaction, the company will receive a licensing fee for the Nav1.8 project from AbbVie. In addition, AbbVie will also support the development of Nav1.8 inhibitors under the authorized variety to a certain extent of research and development costs for clinical concept verification under the collaboration.